The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy
Upregulation of SFK-signaling is found in a subset of chemoresistant tumors and is persistent in metastatic lesions. Based on pre-clinical results, these patients may respond favorably to treatment targeting SFKs.
Authors
- Abhilash Pandya (ORCID: https://orcid.org/0000-0002-7713-3050)
- Maria Aanesland Dahle (ORCID: https://orcid.org/0009-0003-0692-4984)
- Kotryna Seip (ORCID: https://orcid.org/0000-0001-5936-7294)
- Lina Prasmickaite (ORCID: https://orcid.org/0000-0002-8358-7964)
- Solveig Pettersen
- Sigve Nakken (ORCID: https://orcid.org/0000-0001-8468-2050)
- Eleni Skourti (ORCID: https://orcid.org/0000-0001-6008-0549)
- Olav Engebraaten (ORCID: https://orcid.org/0000-0002-0986-6957)
- Gunhild Mari Mælandsmo (ORCID: https://orcid.org/0000-0002-4797-1600)
- Alexander Kristian (ORCID: https://orcid.org/0009-0005-0623-9949)
- Mads Haugland Haugen (ORCID: https://orcid.org/0000-0002-7143-2594)
- Geir Frode Øy
- Eivind Valen Egeland (ORCID: https://orcid.org/0000-0002-7273-7277)
Institutions
- Oslo University Hospital (NO)
- University of Oslo (NO)
- Vestre Viken Hospital Trust (NO)
- Norwegian Cancer Society (NO)
- UiT The Arctic University of Norway (NO)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2024-10-10
- DOI
- https://doi.org/10.1038/s41416-024-02875-5
- Citations
- 9
- Primary Topic
- Cancer-related Molecular Pathways
- Type
- article
- Field-Weighted Citation Impact
- 2.54